DBV Technologies S.A. (DBVT): Price and Financial Metrics


DBV Technologies S.A. (DBVT): $1.53

0.10 (+7.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DBVT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DBVT Stock Price Chart Interactive Chart >

Price chart for DBVT

DBVT Price/Volume Stats

Current price $1.53 52-week high $6.47
Prev. close $1.43 52-week low $1.15
Day low $1.48 Volume 27,000
Day high $1.57 Avg. volume 205,886
50-day MA $1.43 Dividend yield N/A
200-day MA $2.70 Market Cap 187.19M

DBV Technologies S.A. (DBVT) Company Bio


DBV Technologies SA has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. The company was founded in 2002 and is based in Bagneux, France.


DBVT Latest News Stream


Event/Time News Detail
Loading, please wait...

DBVT Latest Social Stream


Loading social stream, please wait...

View Full DBVT Social Stream

Latest DBVT News From Around the Web

Below are the latest news stories about DBV Technologies SA that investors may wish to consider to help them evaluate DBVT as an investment opportunity.

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 3, 2022 at 5:00 p.m. ET to report full year 2021 financial results and provide a corporate update. This call is accessible via the belo

Yahoo | February 24, 2022

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

Montrouge, France, February 22, 2022 DBV Technologies to Participate in Upcoming AAAAI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, February 24 – February 28, 2022. Two scientific presentations have been accepted, including one clinical and one non-clinical poster. DBV w

Yahoo | February 22, 2022

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 8:40 am ET. A webcast of the presentation will be available on the Investors & Media se

Yahoo | February 14, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022

Monthly information regarding the total number of voting rights andtotal number of shares of the Company as of January 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market: NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights01/31/202255,095,762 Total gross of voting rights: 55,095,762 Total net* of voting rights: 54,925,155 * Total net = total number of voting rights attached to shares – shares witho

Yahoo | February 9, 2022

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 21, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. As of December 31, 2021, the following assets appeared on the liquidity account: 153,631 DBV Technologies shares;€ 175,542.33. Upon signing the liquidity contract

Yahoo | January 21, 2022

Read More 'DBVT' Stories Here

DBVT Price Returns

1-mo 19.53%
3-mo 15.04%
6-mo -50.16%
1-year -73.85%
3-year -83.37%
5-year -95.40%
YTD -4.38%
2021 -38.93%
2020 -75.51%
2019 66.67%
2018 -73.90%
2017 -29.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5218 seconds.